Allarity Therapeutics, Inc. (ALLR) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-28

Key Insights

USPTO issued a Notice of Allowance for Allarity's DRP® companion diagnostic patent application specific to stenoparib, which strengthens intellectual property protection for a key diagnostic asset tied to their drug development pipeline.
The patent allowance for a companion diagnostic is strategically significant as it provides regulatory and competitive moats for stenoparib commercialization, potentially enabling precision medicine positioning and differentiation in the market.
As an emerging growth company, Allarity is building patent coverage that could support future partnering opportunities, licensing deals, or standalone commercialization of both the therapeutic and diagnostic components.

Want the newest filings?

This analysis covers the filing from 2026-04-28. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-22

Allarity Therapeutics announced publication of two scientific posters at the AACR Annual Meeting 2026, indicating ongoing research progress and clinical development activities in oncology.
The filing is classified as 'Other Matters' under Item 8.01, suggesting this is a routine announcement of scientific presentations rather than a material corporate event or financial disclosure.
As an emerging growth company, Allarity continues to leverage scientific conferences for visibility and validation of its therapeutic pipeline, though the 8-K provides no details on the specific research findings or clinical implications.

Filed: 2026-04-01

Allarity Therapeutics, Inc. has reported its financial results for the fiscal year ended December 31, 2025. This information is material to investors as it provides an update on the company's financial performance and condition.
The company's press release containing the financial results has been attached as an exhibit to the 8-K filing, allowing investors to review the detailed financial information.
As an emerging growth company, Allarity Therapeutics has the option to take advantage of the extended transition period for complying with new or revised financial accounting standards, which could impact its future financial reporting.

Filed: 2026-03-09

Allarity Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital, which provides additional funding to support the company's ongoing operations and development efforts.
The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards, indicating a focus on timely compliance with reporting requirements.
The filing does not provide any information about the company's financial performance, product pipeline, or other strategic developments, limiting the insights that can be derived from this 8-K filing alone.

Filed: 2026-03-06

Allarity Therapeutics, Inc. entered into a $20.93 million note purchase agreement with Streeterville Capital, LLC, which includes a $10.93 million promissory note and a $10 million secured promissory note.
The note purchase agreement allows for a potential note exchange where the company can exchange $2.5 million of the $10 million B Note for an A Note, providing more flexibility in managing the debt.
The notes carry interest rates of 9% and 5% per annum, respectively, and have a maturity of 18 months, with the company having the ability to prepay the notes at any time.

Filed: 2026-02-04

Allarity Therapeutics has initiated a new Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer, which could expand the company's pipeline and treatment options.
The company's announcement of the new clinical trial enrollment opening indicates continued progress in its drug development efforts and a commitment to advancing its pipeline.
As an emerging growth company, investors should monitor Allarity Therapeutics' future financial and operational performance as the company continues to develop its therapies.

Filed: 2026-01-29

Allarity Therapeutics entered into a $6 million common stock purchase agreement with Tumim Stone Capital, providing the company access to additional capital through a flexible equity line facility.
The agreement includes an 'Exchange Cap' that limits the number of shares Allarity can issue under the facility to 19.99% of the current outstanding shares, unless shareholder approval is obtained.
Allarity will need to submit proposals to shareholders at the next annual meeting to approve a waiver of the Exchange Cap and potentially increase the authorized shares, in order to fully utilize the equity line.

Other reports for Allarity Therapeutics, Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.